Eriocalyxin B blocks human SW1116 colon cancer cell proliferation, migration, invasion, cell cycle progression and angiogenesis via the JAK2/STAT3 signaling pathway

Lu,Yun‑Min; Chen,Wei; Zhu,Jin‑Shui; Chen,Wei‑Xiong; Chen,Ni‑Wei

doi:10.3892/mmr.2016.4800

Eriocalyxin B blocks human SW1116 colon cancer cell proliferation, migration, invasion, cell cycle progression and angiogenesis via the JAK2/STAT3 signaling pathway

Authors:
- Yun‑Min Lu
- Wei Chen
- Jin‑Shui Zhu
- Wei‑Xiong Chen
- Ni‑Wei Chen
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: January 19, 2016 https://doi.org/10.3892/mmr.2016.4800
Pages: 2235-2240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eriocalyxin B, a natural ent-kaurene diterpene compound, has been shown to prevent carcinogenesis and tumor development. However, little is known regarding the mechanism underlying the antitumor activity of Eriocalyxin B in human colon cancer. The aim of the present study was to examine the role of Eriocalyxin B in SW1116 cells, and to verify the hypothesis that the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway may serve as a therapeutic target in human colon cancer treatment. Cell proliferation was measured with a Cell Counting kit‑8 assay, and the cell cycle was assessed by flow cytometry. Cell migration and invasion were measured by Transwell analysis. In addition, western blot analysis was performed to detect the protein expression levels in SW1116 cells treated with various concentrations of Eriocalyxin B. The results demonstrated that 1 µmol/l Eriocalyxin B was effective at inhibiting JAK2 and STAT3 phosphorylation, followed by the downregulation of JAK2 and STAT3 downstream target expression, which resulted in the inhibition of cell proliferation, migration, invasion and angiogenesis. Eriocalyxin B also suppressed the expression of proliferation‑associated protein (proliferating cell nuclear antigen) and angiogenesis‑associated proteins (vascular endothelial growth factor and vascular endothelial growth factor receptor 2), as well as that of migration- and invasion‑associated proteins (matrix metalloproteinase 2 and 9). These results suggested that Eriocalyxin B may suppress JAK2/STAT3 signaling, and thus act as a therapeutic or preventive agent in the treatment of human colon cancer.

View Figures

View References

1	Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009. View Article : Google Scholar : PubMed/NCBI
2	Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: Clinical implications. Clin Cancer Res. 13:1362–1366. 2007. View Article : Google Scholar : PubMed/NCBI
3	Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB and Grandis JR: Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition and resistance to epidermal growth factor receptor targeting. Clin Cancer Res. 14:7682–7690. 2008. View Article : Google Scholar : PubMed/NCBI
4	Park KW, Kundu J, Chae IG, Kim DH, Yu MH, Kundu JK and Chun KS: Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells. Int J Oncol. 44:1309–1315. 2014.PubMed/NCBI
5	Shen A, Chen Y, Hong F, Lin J, Wei L, Hong Z, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3. Oncol Rep. 28:2125–2130. 2012.PubMed/NCBI
6	Lee J, Kim JC, Lee SE, Quinley C, Kim H, Herdman S, Corr M and Raz E: Signal transducer and activator of transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (SNAI) protein stability. J Biol Chem. 287:18182–18189. 2012. View Article : Google Scholar : PubMed/NCBI
7	Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, et al: Stat3 is a negative regulator of intestinal tumor progression in Apc min mice. Gastroenterology. 138:1003–1011. 2010. View Article : Google Scholar
8	Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X and He J: Annual report on status of cancer in China, 2010. Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
9	Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al: Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PloS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
10	Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L and Sun B: IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 13:592013. View Article : Google Scholar : PubMed/NCBI
11	Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 23:1187–1193. 2003.PubMed/NCBI
12	Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ and Sun XJ: Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ. 14:306–317. 2007. View Article : Google Scholar
13	Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T and Mor G: Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol. 65:438–447. 2011. View Article : Google Scholar
14	Li L, Yue GG, Lau CB, Sun H, Fung KP, Leung PC, Han Q and Leung PS: Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways. Toxicol Appl Pharmacol. 262:80–90. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang YW, Jiang XX, Chen QS, Shi WY, Wang L, Sun HD, Shen ZX, Chen Z, Chen SJ and Zhao WL: Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways. Exp Hematol. 38:191–201. 2010. View Article : Google Scholar : PubMed/NCBI
16	Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG and Yang JH: Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res. 16:509–519. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT and Yang PC: Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol. 65:99–110. 2004. View Article : Google Scholar : PubMed/NCBI
19	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
20	Moghimi-Dehkordi B and Safaee A: An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 4:71–75. 2012. View Article : Google Scholar : PubMed/NCBI
21	Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007. View Article : Google Scholar
22	Rivat C, Rodrigues S, Bruyneel E, Piétu G, Robert A, Redeuilh G, Bracke M, Gespach C and Attoub S: Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 65:195–202. 2005.PubMed/NCBI
23	Lu Y, Chen B, Song JH, Zhen T, Wang BY, Li X, Liu P, Yang X, Zhang QL, Xi XD, et al: Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells. Proc Natl Acad Sci USA. 110:2258–2263. 2013. View Article : Google Scholar : PubMed/NCBI
24	Leung CH, Grill SP, Lam W, Gao W, Sun HD and Cheng YC: Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner. Mol Pharmacol. 70:1946–1955. 2006. View Article : Google Scholar : PubMed/NCBI
25	Coupland VH, Lagergren J, Lüchtenborg M, Jack RH, Allum W, Holmberg L, Hanna GB, Pearce N and Møller H: Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: A population-based study in England, 2004–2008. Gut. 62:961–966. 2013. View Article : Google Scholar
26	Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, et al: Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis. Gut. 63:236–243. 2014.
27	Zucker S and Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
28	Langers A, Verspaget H, Hawinkels L, Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW and Sier CF: MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Brit J Cancer. 106:1495–1498. 2012. View Article : Google Scholar : PubMed/NCBI
29	Ahluwalia A, Jones MK, Matysiak-Budnik T and Tarnawski AS: VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Curr Pharm Design. 20:1041–1044. 2014. View Article : Google Scholar
30	Jayasinghe C, Simiantonaki N, Habedank S and Kirkpatrick CJ: The relevance of cell type-and tumor zone-specific VEGFR-2 activation in locally advanced colon cancer. J Exp Clin Cancer Res. 34:422015. View Article : Google Scholar
31	Kim JE, Patel M, Ruzevick J, Jackson CM and Lim M: STAT3 activation in glioblastoma: Biochemical and therapeutic implications. Cancers (Basel). 6:376–395. 2014. View Article : Google Scholar
32	Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, Resnick MB and Chatterjee D: RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer. 13:4632013. View Article : Google Scholar : PubMed/NCBI
33	Dave B, Landis MD, Tweardy D, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D and Lewis MT: Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PloS One. 7:e302072012. View Article : Google Scholar : PubMed/NCBI
34	Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J and Fang JY: Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl). 90:1037–1046. 2012. View Article : Google Scholar
35	Lo HW, Cao X, Zhu H and Ali-Osman F: Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
36	Fletcher S, Turkson J and Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 3:1159–1168. 2008. View Article : Google Scholar : PubMed/NCBI